Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

GW Pharmaceuticals begins phase I study of cannabinoid GWP-42006 for epilepsy

Sep. 19, 2013

Eslicarbazepine acetate meets primary endpoint in two phase III epilepsy studies

Sep. 19, 2013

Acacia Pharma initiates phase III studies of APD-421 for PONV

Sep. 19, 2013

First muscarinic acetylcholine M5 receptor NAM discovered

Sep. 18, 2013

Novel PDE10A inhibitors described by Lundbeck

Sep. 18, 2013

Alemtuzumab approved for multiple sclerosis in the E.U.

Sep. 17, 2013

Evotec AG and Harvard Stem Cell Institute form CureMN collaboration

Sep. 17, 2013

Oligomerix receives NIH grant for Alzheimer's disease therapeutic discovery

Sep. 16, 2013

Omeros reports additional data from OMS-824 program

Sep. 16, 2013

Allergan discloses novel S1P1 receptor ligands for pain and other disorders

Sep. 16, 2013

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...